This information is intended for healthcare professionals based in Belgium and Luxembourg.
If you are not a healthcare professional, click here

Opdivo_Yervoy_Logo Opdivo_Yervoy_Logo Opdivo_Logo Opdivo_Chemotherapy_Logo

Mesothelioma

THE FIRST AND ONLY DUAL IMMUNOTHERAPY IN 1L uMPM

View indication details

  • OPDIVO in combination with ipilimumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma.
Expert opinion

Pleural Mesothelioma
State of the art in 2022
with new perspectives

ECLIPSE webinar series for continuous I-O learning via live peer-to-peer clinical practice exchanges

Product information

A short video on
the rationale of combining
OPDIVO and YERVOY
in collaboration with
P. Coulie

Dosing scheme
OPDIVO+YERVOY
in 1L uMPM

Practical user guide
based on OPDIVO SmPC

Patient & nurse materials

Patient support program

OPDIVO + YERVOY

A diary for your patients treated with
OPDIVO + YERVOY

www.immunooncology.be

An educational website
on immunotherapy
for your nurses

For more patient & nurse materials
click here

1L uMPM, first-line unresected pleural mesothelioma; CT, chemotherapy irAE(s), immune-related adverse event(s)